Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Korea Arlico Pharm Co., Ltd. (260660:KRX), powered by AI.
Korea Arlico Pharm Co., Ltd. is currently trading at ₩3,700. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Korea Arlico Pharm Co., Ltd. on Alpha Lenz.
Korea Arlico Pharm Co., Ltd.'s P/E ratio is -10.4.
“Korea Arlico Pharm Co., Ltd. trades at a P/E of -10.4 (undervalued) with modest ROE of -6.4%. 3Y revenue CAGR of 10.8% highlights clear growth momentum.”
Ask for details →Korea Arlico Pharm Co., Ltd. is a prominent pharmaceutical company engaged in the development, manufacture, and distribution of medicinal products. Specializing in the production of both prescription drugs and over-the-counter medicines, the company plays a vital role in the healthcare industry. Its robust portfolio includes therapeutics aimed at treating a variety of ailments, contributing significantly to public health. Korea Arlico Pharm is noted for its emphasis on innovation and rigorous quality control measures, ensuring the safety and efficacy of its products. Operating in the competitive landscape of pharmaceuticals, the company serves a diverse clientele including hospitals, pharmacies, and healthcare providers. As a participant in the broader healthcare and pharmaceuticals sector, Korea Arlico Pharm Co., Ltd. is pivotal in addressing the demands of an aging population and the growing need for effective medical interventions globally. The company's continuous investment in research and development underscores its commitment to advancing medical science and delivering high-quality healthcare solutions.
“Korea Arlico Pharm Co., Ltd. trades at a P/E of -10.4 (undervalued) with modest ROE of -6.4%. 3Y revenue CAGR of 10.8% highlights clear growth momentum.”
Ask for details →Korea Arlico Pharm Co., Ltd. (ticker: 260660) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $56.7B.
The current price is ₩3,700 with a P/E ratio of -10.37x and P/B of 0.7x.
ROE is -6.35% and operating margin is -2.71%. Annual revenue is $190.4B.